Muscarinic Agonist Therapy of Alzheimer's Disease
- 1 July 1986
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 43 (7), 659-661
- https://doi.org/10.1001/archneur.1986.00520070017009
Abstract
• Cholinergic projections to the cerebral cortex from certain basal forebrain nuclei degenerate in Alzheimer's disease. Nevertheless, attempts to alleviate this disorder through the administration of drugs that increase the availability of acetylcholine to postsynaptic receptor sites have generally yielded disappointing results. In an attempt to evaluate the therapeutic efficacy of cholinomimetics that act independently of the presynaptic cholinergic terminals, a double-blind, placebo-controlled trial of the muscarinic agonist RS-86 (2-ethyl-8 methyl-2,8 diazospiro [4.5]-decane-1,3-dione hydrobromide) was undertaken. Eight patients with Alzheimer's disease with mild to moderately advanced dementia received RS-86 orally at maximum individually tolerated dose levels for eight days. Although some verbal and visuospatial tests showed slight alterations, no consistent overall change in cognitive performance could be discerned. These results lend further support to the view that short-term administration of cholinomimetic monotherapies may fail in the symptomatic treatment of Alzheimer's dementia.Keywords
This publication has 4 references indexed in Scilit:
- Ear asymmetries in dichotic listening tasks which increase in difficultyBrain and Language, 1985
- Effects of RS 86, an orally active cholinergic agonist, on sleep in manPsychiatry Research, 1984
- No effect from double‐blind trial of physostigmine and lecithin in Alzheimer diseaseAnnals of Neurology, 1983
- Memory and cognitive function in manNeurology, 1977